The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs might play a role in neoadjuvant treatment of women with breast cancer.
References
[1]
Mauri, D.; Pavlidis, N.; Ioannidis, J.P. Neoadjuvant vs. adjuvant systemic treatment in breast cancer: A meta-analysis. J. Natl. Cancer Inst. 2005, 97, 188–194, doi:10.1093/jnci/dji021.
[2]
Mieog, J.S.; van der Hage, J.A.; van de Velde, C.J. Neoadjuvant chemotherapy for operable breast cancer. Br. J. Surg. 2007, 94, 1189–1200, doi:10.1002/bjs.5894.
[3]
Ottewell, P.D.; Monkkonen, H.; Jones, M.; Lefley, D.V.; Coleman, R.E.; Holen, I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl. Cancer Inst. 2008, 100, 1167–1178, doi:10.1093/jnci/djn240.
[4]
Valachis, A.; Polyzos, N.P.; Coleman, R.E.; Gnant, M.; Eidtmann, H.; Brufsky, A.M.; Aft, R.; Tevaarwerk, A.J.; Swenson, K.; Lind, P.; et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis. Oncologist 2013, 18, 353–361, doi:10.1634/theoncologist.2012-0261.
[5]
Yan, T.; Yin, W.; Zhou, Q.; Jiang, Y.; Du, Y.; Shao, Z.; Lu, J. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. Eur. J. Cancer 2012, 48, 187–195.
[6]
Winter, M.C.; Holen, I.; Coleman, R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev. 2008, 34, 453–475, doi:10.1016/j.ctrv.2008.02.004.
[7]
Aapro, M.; Abrahamsson, P.A.; Body, J.J.; Coleman, R.E.; Colomer, R.; Costa, L.; Crino, L.; Dirix, L.; Gnant, M.; Gralow, J.; et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann. Oncol. 2008, 19, 420–432.
[8]
Pavlakis, N.; Schmidt, R.; Stockler, M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 2005, 3, doi:10.1002/14651858.CD003474.pub2.
[9]
Van Beek, E.R.; Lowik, C.W.; Ebetino, F.H.; Papapoulos, S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone 1998, 23, 437–442, doi:10.1016/S8756-3282(98)00120-3.
[10]
Russell, R.G.; Muhlbauer, R.C.; Bisaz, S.; Williams, D.A.; Fleisch, H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif. Tissue Res. 1970, 6, 183–196.
[11]
Dunford, J.E.; Thompson, K.; Coxon, F.P.; Luckman, S.P.; Hahn, F.M.; Poulter, C.D.; Ebetino, F.H.; Rogers, M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296, 235–242.
[12]
Kavanagh, K.L.; Guo, K.; Dunford, J.E.; Wu, X.; Knapp, S.; Ebetino, F.H.; Rogers, M.J.; Russel, R.G.; Opperman, U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. USA 2006, 103, 7829–7834, doi:10.1073/pnas.0601643103.
[13]
Luckman, S.P.; Hughes, D.E.; Coxon, F.P.; Graham, R.; Russel, G.; Rogers, M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner Res. 1998, 13, 581–589, doi:10.1359/jbmr.1998.13.4.581.
Plotkin, L.I.; Weinstein, R.S.; Parfitt, A.M.; Roberson, P.K.; Manolagas, S.C.; Bellido, T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 1999, 104, 1363–1374, doi:10.1172/JCI6800.
[16]
Mundy, G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2, 584–593, doi:10.1038/nrc867.
[17]
Roodman, G.D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 2001, 19, 3562–3571.
[18]
Coleman, R.E. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? Eur. J. Cancer 2009, 45, 1909–1915, doi:10.1016/j.ejca.2009.04.022.
[19]
Fournier, P.; Boissier, S.; Filleur, S.; Guglielmi, J.; Cabon, F.; Colombel, M.; Clezardin, P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002, 62, 6538–6544.
[20]
Santini, D.; Vincenzi, B.; Galluzzo, S.; Battistoni, F.; Rocci, L.; Venditti, O.; Schiavon, G.; Angeletti, S.; Uzzali, F.; Caraglia, M.; et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 2007, 13, 4482–4486, doi:10.1158/1078-0432.CCR-07-0551.
[21]
Gober, H.J.; Kistowska, M.; Angman, L.; Jeno, P.; Mori, L.; de Libero, G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 2003, 197, 163–168, doi:10.1084/jem.20021500.
[22]
Benzaid, I.; Monkkonen, H.; Stresing, V.; Bonnelye, E.; Green, J.; Monkkonen, J.; Touraine, J.L.; Clezardin, P. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011, 71, 4562–4572, doi:10.1158/0008-5472.CAN-10-3862.
[23]
Benzaid, I.; Monkkonen, H.; Bonnelye, E.; Monkkonen, J.; Clezardin, P. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vgamma9Vdelta2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin. Cancer Res. 2012, 18, 6249–6259, doi:10.1158/1078-0432.CCR-12-0918.
[24]
Rogers, T.L.; Holen, I. Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med. 2011, 9, 177, doi:10.1186/1479-5876-9-177.
[25]
Neville-Webbe, H.L.; Rostami-Hodjegan, A.; Evans, C.A.; Coleman, R.E.; Holen, I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int. J. Cancer 2005, 113, 364–371, doi:10.1002/ijc.20602.
[26]
Ottewell, P.D.; Woodward, J.K.; Lefley, D.V.; Evans, C.E.; Coleman, R.E.; Holen, I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol. Cancer Ther. 2009, 8, 2821–2832, doi:10.1158/1535-7163.MCT-09-0462.
[27]
Ottewell, P.D.; Deux, B.; Monkkonen, H.; Cross, S.; Coleman, R.E.; Clezardin, P.; Holen, I. Differential effect of doxorubicin and zoledronic acid on intraosseous vs. extraosseous breast tumor growth in vivo. Clin. Cancer Res. 2008, 14, 4658–4666, doi:10.1158/1078-0432.CCR-07-1545.
[28]
Holen, I.; Wang, N.; Reeves, K.J.; Fowles, A.M.; Croucher, P.I.; Eaton, C.L.; Ottewell, P.D. Zoledronic acid specifically inhibits development of bone metastases in the postmenopausal setting—Evidence from an in vivo breast cancer model. Cancer Res. 2012, 72, doi:10.1158/0008-5472.SABCS12-PD07-08.
[29]
Diel, I.J.; Solomayer, E.F.; Costa, S.D.; Gollan, C.; Goerner, R.; Wallwiener, R.; Kaufmann, M.; Bastert, G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 1998, 339, 357–363, doi:10.1056/NEJM199808063390601.
[30]
Diel, I.J.; Jaschke, A.; Solomayer, E.F.; Gollan, C.; Bastert, C.; Sohn, C.; Schuetz, F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up. Ann. Oncol. 2008, 19, 2007–2011, doi:10.1093/annonc/mdn429.
[31]
Powles, T.; Paterson, A.; McCloskey, E.; Schein, P.; Scheffler, B.; Tidy, A.; Ashley, S.; Smith, I.; Ottestad, L.; Kanis, J. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer (ISRCTN83688026). Breast Cancer Res. 2006, 8, 13.
[32]
Saarto, T.; Blomqvist, C.; Virkkunen, P.; Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial. J. Clin. Oncol. 2001, 19, 10–17.
[33]
Gnant, M.; Mlineritsch, B.; Stoeger, H.; Luschin-Ebengreuth, H.; Heck, D.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Pristauz, G.; et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-Month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011, 12, 631–641, doi:10.1016/S1470-2045(11)70122-X.
[34]
Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, H.; Postlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 2009, 360, 679–691, doi:10.1056/NEJMoa0806285.
[35]
Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Stoeger, H.; Dubsky, P.; Jakesz, R.; Singer, C.; Eidtmann, H.; Fesl, C.; Eiermann, W.; et al. Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res. 2011, 71, doi:10.1158/0008-5472.SABCS11-S1-2.
[36]
Brufsky, A.M.; Harker, W.G.; Beck, J.T.; Bosserman, L.; Vogel, C.; Seidler, C.; Jin, L.; Warsi, G.; Argonza-Aviles, E.; Hohneker, J.; et al. Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012, 118, 1192–1201, doi:10.1002/cncr.26313.
[37]
Coleman, R.; de Boer, R.; Eidtmann, H.; Llombart, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Sleeboom, H.P.; Forbes, J.; Barrios, C.; et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann. Oncol. 2013, 24, 398–405, doi:10.1093/annonc/mds277.
[38]
Llombart, A.; Frassoldati, A.; Paija, O.; Sleeboom, H.P.; Jerusalem, G.; Mebis, J.; Deleu, I.; Miller, J.; Schenk, N.; Neven, P. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-Month analysis of the E-ZO-FAST trial. Clin. Breast Cancer 2012, 12, 40–48, doi:10.1016/j.clbc.2011.08.002.
[39]
Coleman, R.E.; Marshall, H.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston, S.J.; Grieve, R.J.; Barrett-Lee, P.J.; et al. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 2011, 365, 1396–1405, doi:10.1056/NEJMoa1105195.
[40]
Coleman, R.E.; Winter, M.C.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M.M.; Gil, M.; Ritchie, D.; Passos-Coelho, J.L.; Wheatley, D.; et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 2010, 102, 1099–1105, doi:10.1038/sj.bjc.6605604.
[41]
Van de Ven, S.; Liefers, G.J.; Putter, H.; van Warmerdam, L.J.; Kessels, L.W.; Dercksen, W.; Pepels, M.J.; Maartense, E.; van Laarhoven, H.W.M.; Vriens, B.; et al. Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without zoledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC). Cancer Res. 2012, 72, doi:10.1158/0008-5472.SABCS12-PD07-06.
[42]
Chavez-MacGregor, M.; Brown, E.; Lei, X.; Litton, J.; Meric-Bernstram, F.; Mettendorf, E.; Hernandez, L.; Valero, V.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 2012, 118, 326–332, doi:10.1002/cncr.26144.
[43]
Hasegawa, Y.; Kohno, N.; Horiguchi, J.; Miura, D.; Ishikawa, T.; Hayashi, M.; Takao, S.; Kim, S.J.; Tanino, H.; Miyashita, M.; et al. A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. Cancer Res. 2012, 72, doi:10.1158/0008-5472.SABCS12-PD07-05.
[44]
Horiguchi, J.; Hasegawa, Y.; Miura, D.; Ishikawa, T.; Hayashi, M.; Takao, S.; Kim, S.J.; Tanino, H.; Miyashita, M.; Konishi, M.; et al. A randomized controlled trial comparing zoledronic acid plus chemothearpy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J. Clin. Oncol. 2013, 31, 1029, doi:10.1200/JCO.2012.44.5064.
[45]
Aft, R.; Naughton, M.; Trinkaus, K.; Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Zhai, J.; Kuo, S.; Shannon, W.; Diemer, K.; et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol. 2010, 11, 421–428, doi:10.1016/S1470-2045(10)70054-1.
[46]
Winter, M.C.; Wilson, C.; Syddall, S.P.; Cross, S.S.; Evans, A.; Ingram, C.E.; Jolley, I.J.; Hatton, M.Q.; Freeman, J.V.; Mori, S.; et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer—A randomized biomarker pilot study. Clin. Cancer Res. 2013, 19, 2755–2765, doi:10.1158/1078-0432.CCR-12-3235.
[47]
ClinicalTrials. Available online: http://www.clinicaltrials.gov (accessed on 3 September 2013).
